Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DREaM: Paliperidone Palmitate vs Oral Antipsychotics in Recent-Onset Schizophrenia
NCT02431702Phase 3Completed
- Sponsor
- Janssen Scientific Affairs
- Start
- Jul 2015
- Primary completion
- Nov 2019
- Modality
- Metabolically Activated Prodrugs
- Countries
- 3
01
Overview
A Phase 3 trial of paliperidone palmitate in schizophrenia, schizophreniform disorder, sponsored by Janssen Scientific Affairs. Started Jul 2015; status: completed.
02
Drugs
paliperidone palmitate
03
Conditions
schizophreniaschizophreniform disorder
Beyond the preview
Go deeper on NCT02431702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02431702.